AI Image
Obesity drugs may boost immune response to fight cancer, doctor says
Fox News • • health
Key Points:
- The American Association for Cancer Research's 2026 report highlights obesity as a major risk factor for many cancers and notes that GLP-1 medications, which aid weight loss and metabolic health, may influence cancer risk and outcomes.
- Studies on GLP-1 receptor agonists like Ozempic and Wegovy suggest a potential reduction in cancer risk and improved survival, but evidence remains mixed and primarily retrospective, requiring further randomized clinical trials.
- Dr. Sai Yendamuri's research indicates obesity increases lung cancer risk and that GLP-1 medications may lower cancer recurrence by enhancing the body's immune response rather than directly affecting cancer cells.
- The cancer benefits of GLP-1 drugs may be partly due to weight loss, but further research is needed to determine if benefits occur independently of weight reduction.
- Future trials could establish GLP-1 medications as preventive agents against cancer, underscoring the importance of continued funding for cancer research through institutions like the National Cancer Institute.
